Sunday, October 21, 2018
- 9:00AM-11:00AM
-
Abstract Number: 411
Kinesiophobia and Physical Function Among Adults with Knee Osteoarthritis: Before and after Strength Training Classes
Orthopedics, Low Back Pain and Rehabilitation Poster – ACR/ARHP- 9:00AM-11:00AM
-
Abstract Number: 551
Leflunomide As a Concomitant DMARD Choice for the Biological Treatment Era of Rheumatoid Arthritis
Rheumatoid Arthritis – Treatments Poster I: Strategy and Epidemiology- 9:00AM-11:00AM
-
Abstract Number: 564
Levels of CXCL13 and sICAM1 Correlate with Disease Activity Score in Rheumatoid Arthritis (RA) Patients Treated with Tocilizumab (TCZ)
Rheumatoid Arthritis – Treatments Poster I: Strategy and Epidemiology- 9:00AM-11:00AM
-
Abstract Number: 472
Libman Sacks Endocarditis in Pediatric Systemic Lupus Erythematosus: Clinical Features and Complications
Pediatric Rheumatology – Clinical Poster I: Lupus, Sjögren’s Disease, and Myositis- 9:00AM-11:00AM
-
Abstract Number: 406
Limiting the Risk of Osteoarthritis after Anterior Cruciate Ligament Injury: Are We Missing the Opportunity to Intervene?
Orthopedics, Low Back Pain and Rehabilitation Poster – ACR/ARHP- 9:00AM-11:00AM
-
Abstract Number: 510
Lipid Profile and Cardiovascular Risk in Subjects at Risk for Rheumatoid Arthritis
Rheumatoid Arthritis – Diagnosis, Manifestations, and Outcomes Poster I: Comorbidities- 9:00AM-11:00AM
-
Abstract Number: 527
Long-Term Follow up of Subclinical Interstitial Lung Disease in Rheumatoid Arthritis
Rheumatoid Arthritis – Diagnosis, Manifestations, and Outcomes Poster I: Comorbidities- 9:00AM-11:00AM
-
Abstract Number: 617
Long-Term Outcome of Rituximab in Rheumatoid Arthritis: Real World Experience
Rheumatoid Arthritis – Treatments Poster I: Strategy and Epidemiology- 9:00AM-11:00AM
-
Abstract Number: 748
Long-Term Survival of Renal Transplantation Due to Lupus Nephritis. Comparative Study with Non-Autoimmune Transplantation. Study from a Single Center
Systemic Lupus Erythematosus – Clinical Poster I: Clinical Manifestations and Comorbidity- 9:00AM-11:00AM
-
Abstract Number: 628
Longitudinal Changes in Relative Market Share Proportions of Biologic and Targeted Synthetic Disease-Modifying Anti-Rheumatic Drugs for Treatment of Rheumatoid Arthritis: Descriptive Data from the Ontario Best-Practice Research Initiative Database
Rheumatoid Arthritis – Treatments Poster I: Strategy and Epidemiology- 9:00AM-11:00AM
-
Abstract Number: 574
Longitudinal Efficacy Analysis of Patients with Active Rheumatoid Arthritis and Inadequate Response to Conventional Synthetic Dmards: Response Following Rescue from Baricitinib 2mg to 4mg Once-Daily
Rheumatoid Arthritis – Treatments Poster I: Strategy and Epidemiology- 9:00AM-11:00AM
-
Abstract Number: 787
Longitudinal Follow-up of Anti-Topoisomerase I Positive Patients within the Leiden Systemic Sclerosis Cohort – Prognosis Infaust?
Systemic Sclerosis and Related Disorders – Clinical Poster I- 9:00AM-11:00AM
-
Abstract Number: 562
Low Inflammation on Magnetic Resonance Imaging in Patients with Rheumatoid Arthritis That Achieved Sustained Clinical Remission on Adalimumab
Rheumatoid Arthritis – Treatments Poster I: Strategy and Epidemiology- 9:00AM-11:00AM
-
Abstract Number: 499
Low Inflammatory Burden and Statin Exposure Inhibit Progression and Induce Regression of Early Coronary Plaques in Rheumatoid Arthritis